The 5-year survival rate for prostate cancer has increased from 67% to nearly 100% over the past 20 years.
[ Get More Details ]
The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.
[ Get More Details ]
A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.
[ Get More Details ]
According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.… [ Get More Details ]
Gains in healthy years of life and social value from cancer R&D